Orcinol

CAS# 504-15-4

Orcinol

Catalog No. BCN5612----Order now to get a substantial discount!

Product Name & Size Price Stock
Orcinol: 5mg $6 In Stock
Orcinol: 10mg Please Inquire In Stock
Orcinol: 20mg Please Inquire Please Inquire
Orcinol: 50mg Please Inquire Please Inquire
Orcinol: 100mg Please Inquire Please Inquire
Orcinol: 200mg Please Inquire Please Inquire
Orcinol: 500mg Please Inquire Please Inquire
Orcinol: 1000mg Please Inquire Please Inquire

Quality Control of Orcinol

Number of papers citing our products

Chemical structure

Orcinol

3D structure

Chemical Properties of Orcinol

Cas No. 504-15-4 SDF Download SDF
PubChem ID 10436 Appearance Oil
Formula C7H8O2 M.Wt 124.1
Type of Compound Phenols Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name 5-methylbenzene-1,3-diol
SMILES CC1=CC(=CC(=C1)O)O
Standard InChIKey OIPPWFOQEKKFEE-UHFFFAOYSA-N
Standard InChI InChI=1S/C7H8O2/c1-5-2-6(8)4-7(9)3-5/h2-4,8-9H,1H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Orcinol

The root of Curculigo orchioides Gaertn.

Biological Activity of Orcinol

DescriptionOrcinol glucoside is anxiolytic agent without sedative effect, it improves depressive behaviour in CUMS rats by downregulating HPA axis hyperactivity and increasing BDNF expression and ERK1/2 phosphorylation in the hippocampus.
TargetsERK | BDNF
In vivo

Orcinol glucoside produces antidepressant effects by blocking the behavioural and neuronal deficits caused by chronic stress.[Pubmed: 23838013]

Eur Neuropsychopharmacol. 2014 Jan;24(1):172-80.

This study focused on the antidepressant potential of Orcinol glucoside (OG) and its possible mechanisms of action.
METHODS AND RESULTS:
We established a depressed rat model using 3 consecutive weeks of chronic unpredictable mild stress (CUMS). The antidepressant-like effect of Orcinol glucoside was revealed using the sucrose preference test, the open field test, the forced swimming test (FST), and the tail suspension test (TST). The activity of the hypothalamic-pituitary-adrenal (HPA) axis was evaluated by detecting the serum corticosterone (CORT) concentrations and mRNA expression of corticotrophin-releasing hormone (CRH) in the hypothalamus. The protein expression levels of brain-derived neurotrophic factor (BDNF) and total phosphorylated-ERK1/2 were detected by western blot. The results showed that Orcinol glucoside treatment (1.5, 3, or 6mg/kg) alleviated the depression-like behaviour of rats under CUMS, as indicated by the increased sucrose preference and the decreased immobility in both the FST and TST, although the rearing frequency in the open field test increased only in the group that received the lowest dose (1.5mg/kg OG). Rats that received Orcinol glucoside treatment exhibited reduced serum CORT levels and CRH mRNA expression in the hypothalamus, suggesting that the hyperactivity of the HPA axis in CUMS rats was reversed by Orcinol glucoside treatment. Moreover, Orcinol glucoside treatment upregulated the protein levels of BDNF and phosphorylated-ERK1/2 in the hippocampus, even above control levels.
CONCLUSIONS:
Our findings suggest that Orcinol glucoside improved depressive behaviour in CUMS rats by downregulating HPA axis hyperactivity and increasing BDNF expression and ERK1/2 phosphorylation in the hippocampus.

Protocol of Orcinol

Animal Research

Anxiolytic effects of orcinol glucoside and orcinol monohydrate in mice.[Pubmed: 25429891]

Pharm Biol. 2015 Jun;53(6):876-81.

Anxiety is a common psychological disorder, often occurring in combination with depression, but therapeutic drugs with high efficacy and safety are lacking. Orcinol glucoside (OG) was recently found to have an antidepressive action. To study the therapeutic potential of Orcinol glucoside and Orcinol monohydrate (OM) as anxiolytic agents.
METHODS AND RESULTS:
Anxiolytic effects in mice were measured using the elevated plus-maze, hole-board, and open-field tests. Eight groups of mice were included in each test. Thirty minutes before each test, mice in each group received one oral administration of Orcinol glucoside (5, 10, or 20 mg/kg), OM (2.5, 5, or 10 mg/kg), the positive control diazepam (1 or 5 mg/kg), or control vehicle. Each mouse underwent only one test. Uptake of Orcinol (5 mg/kg) in the brain was qualitatively detected using the HPLC-MS method. RESULTS: Orcinol glucoside (5, 10, and 20 mg/kg) and OM (2.5 and 5 mg/kg) increased the time spent in open arms and the number of entries into open arms in the elevated plus-maze test. Orcinol glucoside (5 and 10 mg/kg) and OM (2.5 and 5 mg/kg) increased the number of head-dips in the hole-board test. At all tested doses, Orcinol glucoside and OM did not significantly affect the locomotion of mice in the open-field test. Orcinol could be detected in the mouse brain homogenates 30 min after oral OM administration, having confirmed that OM is centrally active.
CONCLUSIONS:
The results demonstrated that Orcinol glucoside and OM are anxiolytic agents without sedative effects, indicating their therapeutic potential for anxiety.

Orcinol Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Orcinol Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Orcinol

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 8.058 mL 40.2901 mL 80.5802 mL 161.1604 mL 201.4504 mL
5 mM 1.6116 mL 8.058 mL 16.116 mL 32.2321 mL 40.2901 mL
10 mM 0.8058 mL 4.029 mL 8.058 mL 16.116 mL 20.145 mL
50 mM 0.1612 mL 0.8058 mL 1.6116 mL 3.2232 mL 4.029 mL
100 mM 0.0806 mL 0.4029 mL 0.8058 mL 1.6116 mL 2.0145 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Orcinol

Orcinol glucoside produces antidepressant effects by blocking the behavioural and neuronal deficits caused by chronic stress.[Pubmed:23838013]

Eur Neuropsychopharmacol. 2014 Jan;24(1):172-80.

This study focused on the antidepressant potential of Orcinol glucoside (OG) and its possible mechanisms of action. We established a depressed rat model using 3 consecutive weeks of chronic unpredictable mild stress (CUMS). The antidepressant-like effect of OG was revealed using the sucrose preference test, the open field test, the forced swimming test (FST), and the tail suspension test (TST). The activity of the hypothalamic-pituitary-adrenal (HPA) axis was evaluated by detecting the serum corticosterone (CORT) concentrations and mRNA expression of corticotrophin-releasing hormone (CRH) in the hypothalamus. The protein expression levels of brain-derived neurotrophic factor (BDNF) and total phosphorylated-ERK1/2 were detected by western blot. The results showed that OG treatment (1.5, 3, or 6mg/kg) alleviated the depression-like behaviour of rats under CUMS, as indicated by the increased sucrose preference and the decreased immobility in both the FST and TST, although the rearing frequency in the open field test increased only in the group that received the lowest dose (1.5mg/kg OG). Rats that received OG treatment exhibited reduced serum CORT levels and CRH mRNA expression in the hypothalamus, suggesting that the hyperactivity of the HPA axis in CUMS rats was reversed by OG treatment. Moreover, OG treatment upregulated the protein levels of BDNF and phosphorylated-ERK1/2 in the hippocampus, even above control levels. Our findings suggest that OG improved depressive behaviour in CUMS rats by downregulating HPA axis hyperactivity and increasing BDNF expression and ERK1/2 phosphorylation in the hippocampus.

Anxiolytic effects of orcinol glucoside and orcinol monohydrate in mice.[Pubmed:25429891]

Pharm Biol. 2015 Jun;53(6):876-81.

CONTEXT: Anxiety is a common psychological disorder, often occurring in combination with depression, but therapeutic drugs with high efficacy and safety are lacking. Orcinol glucoside (OG) was recently found to have an antidepressive action. OBJECTIVE: To study the therapeutic potential of OG and Orcinol monohydrate (OM) as anxiolytic agents. MATERIALS AND METHODS: Anxiolytic effects in mice were measured using the elevated plus-maze, hole-board, and open-field tests. Eight groups of mice were included in each test. Thirty minutes before each test, mice in each group received one oral administration of OG (5, 10, or 20 mg/kg), OM (2.5, 5, or 10 mg/kg), the positive control diazepam (1 or 5 mg/kg), or control vehicle. Each mouse underwent only one test. Uptake of Orcinol (5 mg/kg) in the brain was qualitatively detected using the HPLC-MS method. RESULTS: OG (5, 10, and 20 mg/kg) and OM (2.5 and 5 mg/kg) increased the time spent in open arms and the number of entries into open arms in the elevated plus-maze test. OG (5 and 10 mg/kg) and OM (2.5 and 5 mg/kg) increased the number of head-dips in the hole-board test. At all tested doses, OG and OM did not significantly affect the locomotion of mice in the open-field test. Orcinol could be detected in the mouse brain homogenates 30 min after oral OM administration, having confirmed that OM is centrally active. DISCUSSION AND CONCLUSION: The results demonstrated that OG and OM are anxiolytic agents without sedative effects, indicating their therapeutic potential for anxiety.

Keywords:

Orcinol,504-15-4,Natural Products, buy Orcinol , Orcinol supplier , purchase Orcinol , Orcinol cost , Orcinol manufacturer , order Orcinol , high purity Orcinol

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: